TECFIDERA®

TECFIDERA® (dimethyl fumarate) is an oral therapy approved in the United States for the treatment of relapsing forms of multiple sclerosis which is the most common form of the disease. TECFIDERA has been proven to significantly reduce important measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time, while demonstrating a favorable safety and tolerability profile.
 
TECFIDERA is contraindicated in patients with a known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA and can cause anaphylaxis and angioedema, progressive multifocal leukoencephalopathy (PML), lymphopenia and flushing. The most common adverse reactions for TECFIDERA were flushing, mostly mild to moderate in nature, and GI events (i.e., diarrhea, nausea, abdominal pain). These events are most common at the start of therapy and usually decrease over time. Because TECFIDERA may decrease lymphocyte counts, a CBC including lymphocyte count should be obtained before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter.
 
TECFIDERA is also approved in Canada, Australia, Switzerland and the European Union.